JW (Cayman) Therapeutics Co. Ltd (FRA:JNY)

Germany · Delayed Price · Currency is EUR

0.1640

-0.0160 (-8.89%)

Jun 25, 2026, 4:00 PM EDT

-47.77% (1Y)

Market Cap	68.07M -19.5%
Revenue (ttm)	34.54M +79.3%
Net Income	-67.62M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1650
Previous Close	0.1800
Day's Range	0.1580 - 0.1650
52-Week Range	0.1550 - 0.6350
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About FRA:JNY

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (“relma-cel”) as a potential treatment for systemic lupus eryth... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2016

Employees 314

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol JNY

Financial Performance

In 2025, FRA:JNY's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY Financial Statements